Tag: Solitaire

Medtronic gets US FDA clearance for Riptide aspiration system

The Riptide aspiration system is intended for use in the revascularisation of patients with acute ischaemic stroke secondary to intracranial large vessel occlusive disease...

DEFUSE 3 terminated early with high likelihood of benefit in the...

Following an interim analysis of data from the first 182 patients enrolled in DEFUSE 3, the trial has been terminated and is no longer...

Introducing the new Solitaire™ Platinum Revascularization Device

The Solitaire™ Platinum Revascularization Device is the next generation into the Solitaire™ family which has an enhanced meaningful visibility that provides feedback during placement,...

FDA expands indication of Solitaire device

The US Food and Drug Administration (FDA) has cleared an expanded indication for the Solitaire stent retriever device (Medtronic). The FDA now allows the...

Stent retriever technology named as a Top Medical Innovation by Cleveland...

Stent retriever technology has been named by the Cleveland Clinic as a top medical innovation. It was part of a list of the top...

Evidence builds for endovascular treatment of acute ischaemic stroke

With the publication of two more stroke trials, the evidence in favour of endovascular treatment in patients with acute ischaemic stroke has reached new heights. Data from SWIFT PRIME and REVASCAT add to that of three other trials-MR CLEAN, EXTEND-IA and ESCAPE-that have begun to change the face of ischaemic stroke treatment.

Groundbreaking studies find that neurointerventional surgery reduces stroke mortality

Two new clinical trials on the treatment of stroke (ESCAPE and EXTEND IA) demonstrate that neurointerventional surgery significantly increases the number of patients who are able to live independently without major neurological disabilities.